Exome

Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024

Retrieved on: 
Monday, March 4, 2024

HOUSTON, March 04, 2024 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will showcase its latest advancements and research discoveries at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting on March 12-16 in Toronto, Canada.

Key Points: 
  • The presentations shed light on cutting-edge developments in genetic analysis, diagnostic interpretation, and clinical results, underscoring Baylor Genetics’ mission to translate scientific innovation into accessible clinical solutions that improve patient outcomes and advance precision diagnostics.
  • "These presentations reflect our ongoing commitment to advancing the field of genetics and empowering patients, providers, and partners with insights and innovations to transform healthcare and improve lives."
  • Customers and partners interested in attending the breakfast can request an invitation and register here or inquire onsite at the Baylor Genetics booth.
  • Learn more about ACMG’s Annual Clinical Genetics Meeting through the conference website and visit the Baylor Genetics’ website to explore the company’s genetic testing capabilities.

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

Retrieved on: 
Tuesday, February 20, 2024

ET

Key Points: 
  • ET
    STAMFORD, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the fourth quarter and full year of 2023.
  • Exome and genome represented 27% of all test results, up from 16% in the fourth quarter of 2022 and up from 23% in the third quarter of 2023.
  • Adjusted gross margin from continuing operations expanded to 56%, up from 41% in the fourth quarter of 2022 and up from 48% in the third quarter of 2023.
  • Excluding one-time items, representative continuing operations cash burn was $23.9 million in the fourth quarter of 2023.

Asia-Pacific Rare Disease Genetic Testing Market Analysis and Forecasts, 2023-2024 and 2033 - Opportunities in Transitioning Toward Increased Genetics Coverage in Reimbursement Policies - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2024

The "Asia-Pacific Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia-Pacific Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The Asia-Pacific (APAC) rare disease genetic testing market is witnessing notable growth driven by various factors.
  • What are the major market drivers, challenges, and opportunities in the Asia-Pacific rare disease genetic testing market?
  • What are the key development strategies implemented by the key players to stand out in the Asia-Pacific rare disease genetic testing market?

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

Retrieved on: 
Tuesday, February 6, 2024

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.
  • View the full release here: https://www.businesswire.com/news/home/20240206284355/en/
    “Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally.
  • Pairing Twist’s robust NGS workflows with Element’s AVITI technology will offer customers an economical and streamlined approach to next generation sequencing,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • If interested in learning more about the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow, please reach out here .

BioSkryb Genomics to Highlight Power of Next Generation Single-Cell Technology at AGBT 2024

Retrieved on: 
Tuesday, January 30, 2024

As a Bronze Sponsor, BioSkryb will also host a workshop and networking event at the meeting.

Key Points: 
  • As a Bronze Sponsor, BioSkryb will also host a workshop and networking event at the meeting.
  • “Our industry-first next generation single-cell technology offers the most comprehensive view of the integrated genome, transcriptome, and targeted proteins from each cell in a single workflow, and we are thrilled to highlight novel applications of our platforms at AGBT,” said Suresh Pisharody, CEO, BioSkryb.
  • BioSkryb’s events at AGBT 2024 are as follows:
    Jay A.A. West, Ph.D., Co-Founder & CTO, BioSkryb Genomics advances multiomics and highly accurate single-cell analysis with the next generation of single-cell technology.
  • Join BioSkryb and AGBT attendees to mingle with genomics and multiomics thought leaders over top-shelf bourbon selections and gourmet bacon-themed appetizers.

GeneDx Announces Preliminary 2023 Financial Results

Retrieved on: 
Monday, January 8, 2024

STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.

Key Points: 
  • STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.
  • The preliminary, unaudited results presented in this press release for the year ended December 31, 2023, are based on current expectations and are subject to adjustment, as the company completes the preparation of its 2023 year-end consolidated financial statements and its 2023 year-end audit.
  • GeneDx will release financial results for the fourth quarter and full year of 2023 after the market closes on Tuesday, February 20, 2024.
  • On the same day, Katherine Stueland, President and Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of GeneDx, will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.

GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, October 30, 2023

ET

Key Points: 
  • ET
    STAMFORD, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the third quarter of 2023.
  • Test Volume: Total tests resulted in the third quarter of 2023 were nearly 58,000, compared to nearly 45,000 for the third quarter of 2022.
  • Gross Margin: Adjusted gross margin from continuing operations expanded to 48% in the third quarter of 2023, up sequentially from 37% in the second quarter of 2023.
  • Total Company results reported today for the third quarter of 2023 include GeneDx’s continuing operations and the financial impacts of exited Legacy Sema4 business activities.

Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing

Retrieved on: 
Tuesday, October 31, 2023

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Full Length Unique Dual Index Adapters to enable PCR-free whole genome sequencing (WGS) and multiplexing at scale.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Full Length Unique Dual Index Adapters to enable PCR-free whole genome sequencing (WGS) and multiplexing at scale.
  • “With Twist Full Length UDI Adapters, we can enable PCR-free whole genome sequencing for our customers pursuing that approach, including our customers in Europe where PCR-free WGS has gained traction.”
    Twist Full Length UDI Adapters add to Twist’s portfolio of universal adapter systems, which include Twist Universal Adapter System and Twist High Throughput Universal Adapter System.
  • Twist Full Length UDI Adapters include 1,536 indexes and come in automation-friendly configurations of 96 or 384 sets of adapters, giving customers the ability to multiplex anywhere between two and 1,536 samples.
  • The full length UDI adapters can be used in various NGS workflows and for PCR-free whole genome sequencing.

Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress

Retrieved on: 
Friday, October 20, 2023

Exact Sciences is taking a robust and rigorous approach to developing an MCED test, and today unveiled its brand name, Cancerguard.

Key Points: 
  • Exact Sciences is taking a robust and rigorous approach to developing an MCED test, and today unveiled its brand name, Cancerguard.
  • Building upon decades of research, Exact Sciences is designing the Cancerguard test to harness the additive sensitivity of multiple biomarker classes to detect more early-stage cancers.
  • To learn more, visit http://www.exactsciences.com/cancerguard
    The company will host a symposium at the congress titled "Shifting the Paradigm of Cancer Detection: Multi Cancer Early Detection," featuring experts from leading oncology research institutions and Exact Sciences.
  • The European Society for Medical Oncology (ESMO) does not endorse any company, or their products/services.

Global and Regional Rare Disease Genetic Testing Market Analysis & Forecasts Report 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023

The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.